



ILF/Co-Infections Thematic Roundtable on the Road to HCV Eradication

Monday, 20 July 2015, 18:00 – 22:30 PST / Room 301, Vancouver Convention Centre, Vancouver, Canada

CONCEPT NOTE

Dramatic treatment advances for HCV are taking place; direct acting antivirals represent opportunities to cure most HCV-infected individuals. These new therapies offer improvements in sustained virologic response rates, ease of administration, reduced toxicity and shortened duration of treatment, resulting in declarations that HCV could soon be eradicated. Lessons learned from the HIV epidemic will be critical in reaching this ultimate goal of eradicating HCV infection.

The International AIDS Society (IAS) has prioritized HIV co-infections as one of its major initiatives (others focus on paediatric HIV, key populations, and HIV cure). The Industry Liaison Forum (ILF) Thematic Roundtable Series aims to convene experts from diverse organizations (including industry) to discuss topics relevant to these IAS Member Priorities where a multi-stakeholder approach can lead to novel solutions.

This ILF/Co-Infections Thematic Roundtable will take a step further from the 2nd International HIV/Viral Hepatitis Co-Infection Meeting (www.coinfectionmeeting.com) and focus on the development of a general, visionary and long-term agenda for HCV eradication. It will address issues around (1) identifying HCV-infected individuals and reaching key populations (particularly people who inject drugs and men who have sex with men); (2) establishing treatment priorities (e.g., whether or not to prioritize HIV/HCV co-infected individuals); (3) developing new financing models (particularly for middle-income countries); (4) supporting community empowerment; and (5) taking advantage of lessons learned from HIV. The roundtable will provide a space for a multi-stakeholder dialogue, serving to inform about the situation and discuss interventions and organizations that can support existing efforts for wider access to diagnosis, treatment and care for HCV-infected populations. Overview presentations will set the stage and frame some of the issues while an open, roundtable discussion will allow all participants to contribute to the exchange of ideas on the five discussion points listed above.

The main objectives for this meeting are to:

- Highlight recent progresses regarding HCV science and access to diagnostics and treatment
- Provide background data on the epidemiology of hepatitis C and current normative guidelines
- Present the WHO vision with regards to elimination targets towards 2030
- Highlight challenges, opportunities and potential synergies on the road to HCV eradication
- Catalyze collaboration among attendees from different types of organizations.

Thank you for your interest.

Kenneth Mayer
ILF Co-Chair
USA

Manuel Gonçalves
ILF Co-Chair
UK

Marina Klein
HIV Co-Infections Co-Chair
Canada

Jürgen Rockstroh
HIV Co-Infections Co-Chair
Germany



About the IAS Member Priority on HIV Co-Infections

Effective anti-retroviral therapy (ART) has altered the landscape of HIV infection such that AIDS-related morbidity and mortality has vastly diminished among those with access to therapy. However, co-infections with hepatitis B and C viruses (HBV and HCV, respectively), human papilloma virus (HPV) and tuberculosis (TB) continue to cause serious diseases among HIV-infected populations worldwide. Morbidity and mortality in persons living with HIV are increasingly driven by these non HIV related co-infections, which principally impact key populations, including people who inject drugs (PWID) and men who have sex with men (MSM), due to shared routes of HIV transmission. Recently, a range of new treatment options have appeared for viral hepatitis, TB and HPV, which will substantially change current treatment paradigms. The IAS can now translate over 25 years of experience in HIV for these other closely related disease areas and affected populations.

About the Industry Liaison Forum

The ILF is a mechanism to constructively engage all stakeholders (industry and others) on issues in line with IAS Member Priorities. It is designed to take advantage of the IAS's key strengths: its well-respected convening power; its acknowledged independence from industry and other key partners and stakeholders; and its diverse working groups composed of some of the world's top thought leaders and scientific experts in a wide array of fields. This work is guided by a strong, multi-stakeholder advisory group; it aims to enhance the impact of the global response to HIV and related co-morbidities. More information is available on the ILF website (www.iasociety.org/ilf).

The ILF is grateful for the unrestricted support received from its Gold Partners (Gilead Sciences, MSD and ViiV Healthcare), its Silver Partners (AbbVie, Alere and Janssen) and its Bronze Partners (Abbott, Cipla, Female Health Company, Omega Diagnostics, Roche Molecular Systems and Sysmex Corporation). The ILF Thematic Roundtable Series is sponsored by ILF Gold and Silver Partners.